VYVANSE 50 MG CHEWABLE TABLET

LISDEXAMFETAMINE DIMESYLATE
$12.3521per EA
High Outlier
DEA Schedule CII

Strength

50 mg/1

NDC

59417011901

Classification

Brand

Dosage Form

TABLET, CHEWABLE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

LISDEXAMFETAMINE DIMESYLATE

Approval Type

New Drug (NDA)

FDA Application

NDA208510

On Market Since

1/28/2017

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price History

1W

0.0%

1M

+0.1%

3M

+0.2%

6M

+0.1%

1Y

-0.2%

3Y

+4.7%

5Y

+15.7%

All

+27.6%